2-(7-bromo-4-fluoro-1H-pyrrolo[2,3-c]pyridin-3-yl)-2-oxoacetic acid | 639519-63-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡啶类
• 英文名称: 2-(7-bromo-4-fluoro-1H-pyrrolo[2,3-c]pyridin-3-yl)-2-oxoacetic acid
• CAS: 639519-63-4
• 化学式: C₉H₄BrFN₂O₃
• 分子量: 287.045
• InChiKey: UQZYOOVMSWTBBJ-UHFFFAOYSA-N

物化性质

• 沸点：
  486.1±45.0 °C(Predicted)
• 密度：
  2.026±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  83
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-(7-bromo-4-fluoro-1H-pyrrolo[2,3-c]pyridin-3-yl)-2-oxoacetic acid 在 四(三苯基膦)钯 、 氨 、 N,N-二异丙基乙胺 、 3-(二乙氧基邻酰氧基)-1,2,3-苯并三嗪-4-酮 作用下， 以 1,4-二氧六环 、 甲醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 66.0h， 生成 3-[3-[2-(4-benzoylpiperazin-1-yl)-2-oxo-acetyl]-4-fluoro-1H-pyrrolo[2,3-c]pyridin-7-yl]-N-methyl-1H-pyrazole-5-carboxamide
  参考文献：
  名称：

  Inhibitors of Human Immunodeficiency Virus Type 1 (HIV-1) Attachment. 12. Structure–Activity Relationships Associated with 4-Fluoro-6-azaindole Derivatives Leading to the Identification of 1-(4-Benzoylpiperazin-1-yl)-2-(4-fluoro-7-[1,2,3]triazol-1-yl-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-585248)

  摘要：

  A series of highly potent HIV-1 attachment inhibitors with 4-fluoro-6-azaindole core heterocycles that target the viral envelope protein gp120 has been prepared. Substitution in the 7-position of the azaindole core with amides (12a,b), C-linked heterocycles (12c-I), and N-linked heterocycles (12m-u) provided compounds with subnanomolar potency in a pseudotype infectivity assay and good pharmacokinetic profiles in vivo. A predictive model was developed from the initial SAR in which the potency of the analogues correlated with the ability of the substituent in the 7-position of the azaindole to adopt a coplanar conformation by either forming internal hydrogen bonds or avoiding repulsive substitution patterns. 1-(4-Benzoylpiperazin-1-yl)-2-(4-fluoro-7-[1,2,3]triazol-1-yl-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-585248, 12m) exhibited much improved in vitro potency and pharmacokinetic properties than the previous clinical candidate BMS-488043 (1). The predicted low clearance in humans, modest protein binding, and good potency in the presence of 40% human serum for 12m led to its selection for human clinical studies.

  DOI：

  10.1021/jm3016377
• 作为产物：
  描述：

  7-溴-4-氟-1H-吡咯并[2,3-c]吡啶 在 aluminum (III) chloride 、 氯化 1-乙基-3-甲基咪唑 、 水 作用下， 反应 20.0h， 以82%的产率得到2-(7-bromo-4-fluoro-1H-pyrrolo[2,3-c]pyridin-3-yl)-2-oxoacetic acid
  参考文献：
  名称：

  [EN] INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC UREIDO AND THIOUREIDO PIPERAZINE DERIVATIVES
  [FR] INDOLE, AZAINDOLE ET DERIVES DE PIPERAZINE D'UREIDO ET DE THIOUREIDO HETEROCYCLIQUES RELATIFS

  摘要：

  公开号：

  WO2004011425A3

文献信息

• Field-Based Affinity Optimization of a Novel Azabicyclohexane Scaffold HIV-1 Entry Inhibitor
  作者：Megan E. Meuser、Adel A. Rashad、Gabriel Ozorowski、Alexej Dick、Andrew B. Ward、Simon Cocklin

  DOI：10.3390/molecules24081581

  日期：——

  Small-molecule HIV-1 entry inhibitors are an extremely attractive therapeutic modality. We have previously demonstrated that the entry inhibitor class can be optimized by using computational means to identify and extend the chemotypes available. Here we demonstrate unique and differential effects of previously published antiviral compounds on the gross structure of the HIV-1 Env complex, with an azabicyclohexane

  小分子 HIV-1 进入抑制剂是一种极具吸引力的治疗方式。我们之前已经证明，可以通过使用计算手段来识别和扩展可用的化学型来优化进入抑制剂类。在这里，我们展示了先前发表的抗病毒化合物对 HIV-1 Env 复合物的总体结构的独特和不同的影响，其中氮杂双环己烷支架抑制剂对糖蛋白的热稳定性有积极影响。我们证明这些进入抑制剂的甲基三唑 - 氮杂吲哚头部基团的修饰直接影响化合物的效力，并且用胺 - 恶二唑取代甲基三唑通过改善速率动力学使化合物的亲和力比亲本增加了 1000 倍范围。
• DIKETO-PIPERAZINE AND PIPERIDINE DERIVATIVES AS ANTIVIRAL AGENTS
  申请人：Wang Tao

  公开号：US20070249579A1

  公开（公告）日：2007-10-25

  This disclosure provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the disclosure is concerned with diketo piperazine and piperadine derivatives that possess unique antiviral activity. More particularly, the present disclosure relates to compounds useful for the treatment of HIV and AIDS.

  本公开提供具有药物和生物影响特性的化合物，它们的药物组合物和使用方法。具体而言，该公开涉及具有独特抗病毒活性的二酮哌嗪和哌啶衍生物。更具体地说，本公开涉及用于治疗艾滋病毒和艾滋病的化合物。
• Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
  申请人：——

  公开号：US20040110785A1

  公开（公告）日：2004-06-10

  This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with azaindoleoxoacetyl piperazine derivatives. These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS.

  这项发明提供了具有药物和生物影响特性的化合物，它们的药物组合物和使用方法。具体而言，该发明涉及吡啶并咪唑酮乙酰基哌嗪衍生物。这些化合物具有独特的抗病毒活性，无论是单独使用还是与其他抗病毒药物、抗感染剂、免疫调节剂或HIV进入抑制剂结合使用。更具体地，本发明涉及治疗HIV和艾滋病。
• Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides
  申请人：——

  公开号：US20040063744A1

  公开（公告）日：2004-04-01

  This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with new piperidine 4-alkenyl derivatives that possess unique antiviral activity. More particularly, the present invention relates to compounds useful for the treatment of HIV and AIDS. The compounds of the invention for the general Formula I: 1 wherein: Z is 2 Q is selected from the group consisting of: 3 —W— is 4

  这项发明提供了具有药物和生物影响性能的化合物，它们的药物组合物和使用方法。具体而言，该发明涉及具有独特抗病毒活性的新哌啶4-烯基衍生物。更具体地说，本发明涉及用于治疗艾滋病毒和艾滋病的化合物。本发明的化合物为一般式I的化合物： 1 其中： Z是 2 Q是从以下组中选择的： 3 —W—是 4
• Indole, azaindole and related heterocyclic sulfonylureido piperazine derivatives
  申请人：——

  公开号：US20040006090A1

  公开（公告）日：2004-01-08

  This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with sulfonylureido piperazine derivatives of Formula I. These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS. 1 wherein: Z is 2 Q is selected from the group consisting of: 3 —W— is 4 —represents a carbon-carbon bond or does not exist; and A is NR 13 R 14 .

  该发明提供了具有药物和生物影响特性的化合物，它们的药物组合物及使用方法。具体而言，该发明涉及式I的磺酰脲基哌嗪衍生物。这些化合物具有独特的抗病毒活性，无论是单独使用还是与其他抗病毒药物、抗感染药物、免疫调节剂或HIV进入抑制剂结合使用。更具体地，本发明涉及HIV和艾滋病的治疗。其中：Z是；Q是选择自组中的一种；—W—是；—代表碳-碳键或不存在；A是NR13R14。